Thursday, June 27, 2013

Diabetes Drug Maker Suspends Deal With Deen

Deen, who suffers from Type 2 Diabetes, had partnered with the company to promote its diabetes drug Victoza. In a statement the company said the decision was mutual. "Novo Nordisk and Paula Deen have mutually agreed to suspend our patient education 

CHICAGO–GlaxoSmithKline's experimental diabetes drug proved to be at least as good at controlling blood sugar as most–but not one–in a series of late-stage trials reported Monday, building on a body of mixed 

In an R&D field typically characterized by slow progress and incremental gains, Isis Pharmaceuticals jumped out of the ADA pack in Chicago with some stellar mid-stage data from a very small study of a gene-silencing 

Diabetes drug maker Novo Nordisk and Target became the latest companies to distance themselves from Paula Deen on Thursday amid the controversy surrounding the celebrity chef. "Novo Nordisk and Paula Deen have mutually agreed to suspend our 

Ms. Deen, 66, has been the public face of the company's diabetes medication Victoza since January 2012, when she simultaneously announced that she had Type 2 diabetes and endorsed the drug. The timing set off a storm of criticism that Ms. Deen 

Related External Links


Diabetes Drug Maker Suspends Deal With Deen

No comments:

Post a Comment